Coronary Stenosis
Pipeline by Development Stage
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.1yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
Competitive Landscape
8 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (12)
Total enrollment: 3,956 patients across 12 trials
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Diastolic Hyperemia-Free Ratio in Patients With CAD
A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
Diagnostic Accuracy of CCTA-derived Versus AngiogRaphy-dErived QuantitativE Flow Ratio (CAREER) Study
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial
Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package
Shockwave Coronary Lithoplasty Study
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)
Related Jobs in Cardiovascular
AI & Digital Lead M/F/X
Senior Clinical Research Associate - Cardiovascular (EDG-2026033)
Executive Director, Head of Global Site Management
Director, Clinical Trial Liaison - Northern Midwest: Illinois; Indiana; Michigan; Minnesota; Missouri; Iowa; North Dakota
Executive Director, Data, AI & Collaboration Services
Territory Manager- PV - Los Angeles Proper
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.